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Abstract: Human prion diseases, including sporadic, familial, and acquired forms such as 
Creutzfeldt-Jakob disease (CJD), are caused by prions in which an abnormal prion protein 
(PrP
Sc
) derived from its normal cellular isoform (PrP
C
) is the only known component. The 
recently-identified variably protease-sensitive prionopathy (VPSPr) is characterized not 
only by an atypical clinical phenotype and neuropathology but also by the deposition in the 
brain of a peculiar PrP
Sc
. Like other forms of human prion disease, the pathogenesis of 
VPSPr also currently remains unclear. However, the findings of the peculiar features of 
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prions from VPSPr and of the possible association of VPSPr with a known genetic prion 
disease linked with a valine to isoleucine mutation at residue 180 of PrP reported recently, 
may be of great importance in enhancing our understanding of not only this atypical human 
prion disease in particular, but also other prion diseases in general. In this review, we 
highlight the physicochemical and biological properties of prions from VPSPr and discuss 
the pathogenesis of VPSPr including the origin and formation of the peculiar prions.  
Keywords: prions; prion protein; prion disease; Creutzfeldt-Jakob disease (CJD); variably 
protease-sensitive prionopathy (VPSPr); Gerstmann-Sträussler-Scheinker (GSS); mutation; 
proteinase K; antibody; glycosylation; glycoform-selective prion formation; transmissibility  
 
1. Introduction 
Prions are infectious pathogens that are associated with a group of fatal transmissible spongiform 
encephalopathies or prion diseases affecting both animals and humans. They are composed mainly, if 
not entirely, of the pathologic scrapie conformer (PrP
Sc
) and originate from the cellular prion protein 
(PrP
C
) by means of a structural transition from a largely α-helical form to predominantly β-sheets [1]. 
Unlike other infectious agents, such as bacteria, viruses, and fungi, which contain genomes composed 
of either DNA or RNA, prions are the only known infectious pathogens that are devoid of nucleic acid, 
according to the “protein only” hypothesis [1]. Human prion diseases are highly heterogeneous: They 
can be familial, sporadic, or acquired by infection, and include Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker (GSS) disease, fatal insomnia, kuru and variant CJD (vCJD) [2]. Atypical 
human and animal prion diseases have recently been identified including variably protease-sensitive 
prionopathy (VPSPr) in human and Nor98/atypical scrapie in sheep and goats [3–7]. The two atypical 
human and sheep prion diseases are characterized by the deposition of peculiar prions in the brain. No 
mutations have been found in the open reading frame of prion protein gene in the two diseases. While 
Nor98 scrapie is associated with polymorphisms at R154H and L141F, VPSPr is observed in all three 
genotypes of PrP polymorphism at residue 129 of PrP. PrP
Sc
 from the two diseases exhibited a small 
PK-resistant fragment similar to those observed in some of familial prion diseases [4–6,8]. 
2. Dominant Protease-Sensitive PrP
Sc
 Conformer  
In the eleven cases first reported, they were all valine/valine homozygosity at residue 129 of PrP 
and more than half of them had a family history of dementia [4]. Although spongiform degeneration 
and PrP immunostaining were observed, surprisingly, no typical PK-resistant PrP
Sc
 (rPrP
Sc
) was 
detectable in the brain of all cases by conventional Western blotting probing with the widely-used  
anti-PrP antibody 3F4. The 3F4 antibody that has an epitope between residues 106 and 112 [9] 
detected an abnormal PrP in PSPr only after enrichment with gene 5 protein (g5p) and sodium 
phosphotungstate (NaPTA) that are able to bind to abnormally-folded PrP molecules regardless of 
their PK resistance [10,11]. However, more than 70% of the abnormal PrP captured by g5p from these 
cases was sensitive to PK-digestion while only about 10% of captured PrP
Sc
 was PK-sensitive in sCJD. 
Therefore, this atypical human prion disease characterized by the deposition in the brain of dominant 
PK-sensitive PrP
Sc
 (sPrP
Sc
) was initially termed as protease-sensitive prionopathy (PSPr) [4]. 
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Figure 1. Detection of PrP from variably protease-sensitive prionopathy (VPSPr), 
Gerstmann-Sträussler-Scheinker (GSS), and sporadic Creutzfeldt-Jakob disease (sCJD) 
with 129 methionine/methionine (MM) polymorphism and PrP
Sc
 type 1 (sCJDMM1) with 
nine anti-PrP antibodies. A: Diagram of epitope locations of anti-PrP antibodies examined 
on human PrP. Antibodies and their epitopes are: 3F4 (PrP106-112), 1E4 (PrP97-105), 
6D11 (PrP93-109), 8G8 (PrP95-110), Anti-C (PrP220-231), 6H4 (PrP145-152), 9A2 
(PrP99-101), 12B2 (PrP89-93), and V14 (PrP185-196). B through J: Brain homogenates 
from VPSPr, GSS linked to PrP
P102L
 mutation (GSS102), GSS linked to PrP
A117V
 mutation, 
and sCJDMM1 were treated with PK or/PNGase F prior to SDS-PAGE and Western 
blotting with nine different anti-PrP antibodies, respectively. B: 3F4; C: 1E4; D: 6D11; E: 
8G8; F: Anti-C; G: 6H4; H: 9A2; I: 12B2; J: V14. Of the nine antibodies used, 1E4 
exhibits the highest affinity for rPrP
Sc
 from VPSPr. However, 1E4 has a lower affinity for 
rPrP
Sc
 from GSS102 compared to 3F4. It could be due to the PrP
P102L
 mutation that is 
localized within the 1E4 epitope. Since VPSPr20 and VPSPr17 are detectable by 6D11 that 
is against human PrP93-109, their N-terminal domains may start at least from residue 93. 
VPSPr7 is recognized by 1E4 that is against human PrP97-105, suggesting that the N-
terminus of VPSPr7 contains residue 97.  
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3. Pathognomonic Ladder-Like Electrophoretic Profile of Protease-Resistant PrP
Sc
 with a 
Peculiar Immunoreactivity Behavior 
Although undetectable with 3F4 by conventional Western blotting, a ladder-like electrophoretic 
profile of PK-resistant PrP
Sc
 (rPrP
Sc
) was readily detected with an antibody called 1E4, which is 
unprecedented in sporadic human prion diseases [4]. The 1E4 clone was derived from hybridization  
of SP2/0-Ag14 myeloma cells with spleen cells from a PrP-knockout mouse immunized with the 
peptide QWNKPSKPKTN that corresponds to the bovine PrP amino acid sequence 108–119 
(http://www.cellsciences.com/content/p-detail.asp?rowid=8107). While this antibody was mostly used 
for detection of bovine and ovine PrP
Sc
, we demonstrated that this antibody with an epitope localized 
between human PrP residues 97 and 105 (Yuan et al., 2008) exhibiting the highest affinity for PrP
Sc
 of 
PSPr among the nine anti-PrP antibodies we examined including 1E4 (against PrP97-105), 3F4 
(PrP106-112), 6D11 (PrP93-109), 8G8 (PrP95-110), Anti-C (220-231), 6H4 (PrP145-152), 9A2 
(PrP99-101), 12B2 (PrP89-93), and V14 (PrP185-196) (Figure 1). Since the 1E4-detected ladder-like 
electrophoretic profile of rPrP
Sc
 is very unique and was detected repeatedly in all eleven cases, it has 
been considered to be pathognomonic for PSPr.  
The discovery of the pathognomonic molecular feature of PSPr has greatly facilitated the 
identification of this unique type of human prion disease. Bearing this feature of PSPr in mind, we 
reexamined retroprospectively suspected cases referred to the National Prion Disease Pathology 
Surveillance Center (NPDPSC, Cleveland, OH, USA) between 2002 and 2010 including two cases 
from Italy [5]. For newly-referred cases, it has become a routine procedure to re-do Western  
blot analysis with the 1E4 antibody in order to find out the possible cases of PSPr at NPDPSC if  
they are negative for rPrP
Sc
 by Western blotting with 3F4 but positive for H&E staining and 
immunohistochemistry with 3F4.  
4. Polymorphism-Dependent PK-Sensitive and PK-Resistant PrP
Sc
 
In 2010, we first reported that PSPr affects not only subjects homozygous for valine at PrP residue 
129 but also subjects homozygous for methionine (129 MM) or heterozygous for methionine/valine 
(129 MV) [5]. Of the fifteen cases we examined, one of the two Italian cases was previously reported 
by Giaccone et al [3]. Compared to the initially reported PSPr in valine homozygotes, the levels of 
sPrP
Sc
 were significantly decreased while the levels of rPrP
Sc
 were significantly increased in 129 MM 
or 129 MV cases. Interestingly, it seems that the levels of rPrP
Sc
 are dictated by methionine at residue 
129. Vice versa, the levels of sPrP
Sc
 seem to be dictated by valine at residue 129. Although it has been 
well-documented that PrP polymorphism at residue 129 is implicated in mediating susceptibility to the 
disease, phenotypes of disease, and PrP
Sc
 types [2], to our knowledge, our study provided the first 
evidence that the polymorphism may also participate in medicating the amounts of sPrP
Sc
 or rPrP
Sc
 [5]. 
To more precisely reflect the polymorphism-dependent variation in the levels of rPrP
Sc
 or sPrP
Sc
 in  
this newly-identified disease, we revised the original designation as “variably protease-sensitive 
prionopathy” (VPSPr) [5].  
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Figure 2. Schematic diagram of electrophoretic profile of rPrP
Sc
 from VPSPr and 
sCJD probed with 1E4. Without PNGase F treatment, five rPrP
Sc
 fragments are  
detectable with Western blotting including VPSPr26, VPSPr23, VPSPr20, VPSPr17, and 
VPSPr7 from VPSPr while three rPrP
Sc
 fragments are detected including di-, mono-, and 
un-glycosylated PrP from classic sCJD. After PNGase F treatment, three core PrP 
fragments remain in VPSPr including VPSPr20, VPSPr17, and VPSPr7 while only one 
core PrP fragment remains in sCJD. VPSPr26 and VPSPr23 are monoglycosylated forms 
of VPSPr20 and VPSPr17, respectively.  
 
5. The Ladder-Like Electrophoretic Profile of 1E4-Detected rPrP
Sc
 Consisting of Five PrP 
Fragments 
Some of the rPrP
Sc
 fragments became detectable in VPSPr129MM and VPSPr129MV with the 3F4 
antibody, especially in the former. Notably, even though the amounts of rPrP
Sc
 in VPSPr129MM or 
VPSPr129MV were significantly increased compared to those of rPrP
Sc
 in VPSPr129VV, the profile of 
rPrP
Sc
 detected with 3F4 is different from that detected with 1E4. The most significant differences in 
the rPrP
Sc
 fragments detected with the two antibodies were the smallest fragment migrating at 
approximately 7 kDa called VPSPr7 that was detectable with 1E4 but not with 3F4 [5,6]. Except for 
VPSPr7, both 3F4 and 1E4 detected the other four rPrP
Sc
 fragments migrating at ~26 kDa, 23 kDa,  
20 kDa, and 17 kDa, termed VPSPr26, VPSPr23, VPSPr20, and VPSPr 17, respectively, which is 
strikingly different from rPrP
Sc
 observed in classic sCJD (Figure 2). Based on gel migration, VPSPr26 
corresponds to monoglycosylated rPrP
Sc
 of the classic sCJD, whereas VPSPr20 corresponds to 
unglycosylated rPrP
Sc
 of sCJD. Interestingly, no detectable diglycosylated rPrP
Sc
 was observed by both 
3F4 and 1E4 in VPSPr, which was also observed in the first case reported [3]. On the other hand, three 
additional fragments VPSPr23, VPSPr17 and VPSPr7 were not detectable in sCJD. A PK-titration of 
PrP
Sc
 from VPSPr129MM or 129MV on the Western blots probed with 1E4 or 3F4 revealed that 
VPSPr26 and VPSPr20 gradually faded away while VPSPr23 and VPSPr17 became dominant upon 
increases in the PK concentrations, suggesting that VPSPr23 derives from VPSPr26 while VPSPr17 
from VPSPr20. After deglycosylation, we convincingly showed that unglycosylated VPSPr20 decreased 
while VPSPr17 increased. As mentioned above, VPSPr20 may correspond to unglycosylated rPrP
Sc 
of 
sCJD and it may encompass PrP sequence from residue 90 to 231. So, it is most likely that the switch 
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from VPSPr20 to VPSPr17 caused by PK-digestion may be due to cleavage of a C-terminal domain 
since both fragments were detected with antibodies against human PrP97-105 (1E4) and PrP106-112 
(3F4). Moreover, the antibody Anti-C specific for human PrP220-231 detected four rPrP
Sc
 after 
deglycosylation with PNGase F. However, the migration of these fragments detected with Anti-C 
seemed to be different from that of 1E4-detected fragments except for VPSPr20. All these findings 
suggest that conformation of PrP
Sc
 in VPSPr is quite different from that of PrP
Sc
 in sCJD and it may 
have many more PK-cleavage sites of PrP
Sc
 in VPSPr than in sCJD. The cleavages may occur not only 
at the N-terminal domain but also at the C-terminal domain. 
6. Glycoform-Selective Prion Formation in VPSPr and fCJD
V180I 
In general, the four glycoforms of PrP
C
 variably glycosylated at the two N-linked glycosylation 
sites are usually all converted into their PrP
Sc
 counterparts in all human prion diseases [2]. However, 
there are exceptions. Familial CJD linked to either PrP
T183A
 (fCJD
T183A
) or PrP
V180I 
(fCJD
V180I
) 
mutation exhibits an rPrP
Sc
 that lacks the diglycosylated PrP species [12,13]. T183A mutation itself is 
known to completely eliminate the first glycosylation site at residue 181 [14], which is believed to 
account for the lack of diglycosylated rPrP
Sc
. However, the molecular mechanism underlying alteration 
in glycosylation by V180I mutation is unknown. In addition to the two mutations, two cases of atypical 
sporadic CJD have also been reported to lack diglycosylated rPrP
Sc
 [3,15], one of which was 
subsequently proven to be a case of VPSPr [3,5].  
To understand the molecular mechanism underlying the lack of diglycosylated rPrP
Sc
 and formation 
of ladder-like electrophoretic profile of rPrP
Sc
 as well as to investigate the potential association between 
sporadic VPSPr and familial CJD lacking diglycosylated PK-resistant PrP form, we compared their 
individual PrP glycoforms using antibodies that are able to distinguish the two glycosylation  
sites [6,16,17]. Using a combination of in vivo and in vitro assays, we demonstrated that the absence of 
the diglycosylated PrP
Sc
 in both VPSPr and fCJD
V180I
 is associated with the inability of the di- and 
mono-glycosylated PrP
C
 with the intact first glycosylation site (N181) to convert into PrP
Sc
 in the 
brain. Surprisingly, fCJD
V180I
 was detected to have an rPrP
Sc
 that was markedly similar to that observed in 
VPSPr, with a five-step ladder-like electrophoretic profile, a pathognomonic molecular feature of 
VPSPr [6]. Therefore, although VPSPr is linked to wild-type PrP and fCJD
V180I
 is linked to mutant 
PrP, both sporadic VPSPr and fCJD
V180I 
may share a unique glycoform-selective prion formation 
pathway. Moreover, conformation of PrP
Sc
 in the two conditions also may be very similar, as evidenced by 
the generation of a virtually identical electrophoretic profile of rPrP
Sc
 upon PK-treatment. 
Although the molecular mechanism underlying glycoform-selective prion formation is unclear at 
present, there are several clues that may be of significance in understanding this mystery. First, in 
contrast to fCJD
T183A
, both VPSPr and fCJD
V180I 
exhibited an intact glycosylation prior to PK-digestion. 
Moreover, PrP
V180I
 in cultured cells had a typical glycoform profile. It generated detectable typical 
rPrP
Sc
 with diglycosylated PrP form upon PK-treatment, in addition to mono-unglycosylated forms 
although they were detectable only with 1E4 but not with 3F4 [6]. Therefore, PrP
V180I
 mutation itself 
does not eliminate any glycosylation sites and it can be converted into rPrP
Sc
 as does wild-type PrP
C
. 
Second, a decrease in the glycosylation potential value for the first glycosylation site was predicated 
by the N-linked glycosylation prediction algorithm [6], suggesting that PrP
V180I
 may alter the 
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composition of glycans at the first site. Third, diglycosylated PrP or monoglycosylated PrP carrying 
mono181 was not converted into rPrP
Sc
, which was not observed in cultured cells but only observed in 
the brain in which there is an additional wild-type allele. Finally, compared to sCJD, the binding of 
ricinus communis agglutinin I (RCA-I) to monoglycosylated PrP decreased while the binding to 
diglycosylated PrP increased in VPSPr and fCJD
V180I
 [6], suggesting that the two diseases have a 
changed composition of glycans. Therefore, it is possible that glycoform-selective prion formation 
observed in brain involves dominant-negative inhibition caused by the interaction between misfolded 
and normal PrP molecules. The changed composition of glycans at the first site by the mutation may 
alter local conformation around residue 181 that is close to the β-sheets 2/α-helixes 2 loop, the critical 
region implicated in dominant-negative inhibition [18]. Consistent with this hypothesis, it seems that 
there are significant differences in the effect of mutations occurring at either the first or the second 
glycosylation site on the conversion of PrP
C 
into PrP
Sc
. While most of mutations at the first site 
blocked the conversion, none of or a few, if any, mutations at the second site were found to block PrP
C
 
conversion in cell and animal models [19,20]. More specifically, interactions between different PrP
C
 
glycoforms mediate the efficiency of prion formation, which involves glycan-associated steric 
hindrance [21]. The same group also demonstrated that dominant negative inhibition of prion 
formation requires no protein X or any other accessory cofactor [22]. Although no PrP mutations have 
been observed in VPSPr, a similar aberrant glycosylation at N181 caused by a rare stochastic event has 
been proposed to trigger the processes as described for fCJD
V180I
 [6].  
Another possibility to cause glycoform-selective prion formation is that one or more co-factors may 
be operating in VPSPr and fCJD
V180I
 and the co-factors may prevent conversion of diglycosylated PrP 
and mono181 into PrP
Sc
. There may be some implications in the two diseases that other co-factors may 
be involved in the pathogenesis of the diseases. For instance, although linked to the PrP
V180I
 mutation, 
no family history of neurodegenerative disorders has been reported in fCJD
V180I
 cases [23]. On the 
other hand, while no mutations have been identified within the coding sequence (the open reading 
frame) of PrP gene in VPSPr to date, eight out of 26 reported VPSPr cases showed a familial history of 
dementia [5,24]. Indeed, several lines of evidence have indicated that other co-factors may be involved 
in the pathogenesis of prion diseases, including protein X and non-proteinaceous cofactors [25–27]. 
Whether protein X that was initially proposed to directly interact with PrP
C
 is necessary for prion 
formation remains controversial [26,28]. However, genes or proteins that may indirectly trigger the 
conversion of PrP
C
 into PrP
Sc 
may exist. It is possible that a mutation in a specific gene that 
participates in regulating PrP glycosylation may alter glycosylation at the first glycosylation site and 
then causes VPSPr or/and fCJD
V180I
. If this is the case, further investigation of the two diseases may 
provide an opportunity to find out about the existence of such a co-factor.  
7. Transmissibility of VPSPr and fCJD
V180I
  
It has been widely accepted that any prion diseases must be transmissible although there are some 
prion diseases that have not been transmitted yet [29,30]. Before Stanley Prusiner discovered prions 
and coined prion in 1982 [31], the term transmissible spongiform encephalopathy (TSE) had been 
widely used. As indicated by its striking name, a TSE must possess these two major characteristics: 
transmissibility and spongiform degeneration in the central nervous system (CNS). The discovery of 
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prions as infectious protein pathogens, which are free of nuclear acids and which are the cause of 
transmissible spongiform encephalopathies, was a revolutionary development not only for the field in 
particular but also for the life science in general. PrP
Sc
 has in fact been observed in almost all TSE 
identified so far. Identification of PrP
Sc
 has become essential in the current diagnostic criteria for TSE. 
The designation, “prion diseases”, has largely replaced “transmissible spongiform encephalopathy”. 
However, confusion results when it is observed that some prion diseases lack one or two 
characteristics of TSE. Approximately 10% of sporadic CJD and 32% of familial prion diseases were 
non-transmissible in nonhuman primates [32]. Moreover, all GSS, except one-third of GSS
P102L
 cases, 
were difficult to transmit to rodents [33]. Further, the spongiform degeneration typical of TSE is not 
always present in all GSS
P102L
, although diffuse deposits of PrP
Sc
 plus PrP-amyloid plaques are present 
in the CNS [34]. In transgenic mice expressing murine PrP P101L (equivalent to human P102L) and 
challenged with GSS free of spongiform degeneration, neither symptoms nor spongiform degeneration 
was observed despite the presence of PrP-amyloid [35]. Obviously, conditions such as these, which do 
not manifest transmissibility or spongiform degeneration (singly or jointly), should not be considered 
as types of TSE. They do, however, constitute prion diseases. Based on a wealth of data gathered so 
far, one may wonder whether or not prion diseases should now be redefined. Under a reconsidered 
definition, they should include a group of disorders characterized by the accumulation of abnormal PrP 
including protease-sensitive and protease-resistant forms in the brain, regardless of the presence of 
transmissibility and spongiform degeneration. Most importantly, the spectrum of prion diseases must 
not be restrained by the definition of TSE. 
As a prion disease, VPSPr should likewise meet Koch’s postulates as well [36]. So, it would be 
important to investigate the transmissibility of VPSPr that exhibits the peculiar PK-resistant behavior 
of PrP. Preliminary data recently reported by Nonno et al. indicate that transmissibility of VPSPr-
129MM, -129MV and -129VV to bank voles is related to the bank vole methionine / isoleucine 
polymorphism at codon 109 [37]. Furthermore, studies with humanized mice suggest that 
transmissibility of VPSPr is much lower compared to classic sporadic CJD [38]. No clinical 
phenotypes were observed during the normal life span of transgenic mice expressing human PrP-129V 
at approximately 10 fold, following inoculation with brain homogenates from VPSPr-129VV cases. 
Less than 20% of the mice were found to have scattered PrP plaques with minimal or no spongiform 
degeneration, compared to the typical neuropathological changes found in 100% mice inoculated with 
the classic sCJD [38]. Similarly, using protein misfolding cyclic amplification (PMCA) assay, we 
found that the amplification efficiency of PrP
Sc
 from VPSPr is much lower compared to iatrogenic and 
sporadic CJD (Zou et al., unpublished data). To date, there are no reports available demonstrating that 
fCJD
V180I
 is transmissible [39]. Therefore, prions in VPSPr and fCJD
V180I
 exhibit striking similarities 
not only in physicochemical but also in biological properties. In collaboration with Drs. Yong-Sun 
Kim and Robert Petersen, we are generating humanized transgenic mice expressing human PrP
V180I
 
currently and will be testing transmissibility of VPSPr and fCJD
V180I
 with this animal model.
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8. Origin of Prions in VPSPr and fCJD
V180I
 
As mentioned above, prions from VPSPr and fCJD
V18
°
I
 are of unique physicochemical and 
biological properties. Remarkably, they exhibit a high immunoreactivity with the 1E4 antibody  
but a poor reactivity with 3F4 [5,6]. We have demonstrated that the two antibodies have adjacent 
epitopes and especially the 3F4 epitope (PrP106-112) is next to the C-terminus of the 1E4 epitope 
(PrP97-105) [9,40]. Because of the unique localization of the two epitopes, it is most likely that all 
five-step like rPrP
Sc
 fragments from the two diseases contain the 3F4 epitope. So, the poor affinity of 
3F4 for rPrP
Sc
 from VPSPr and fCJD
V180I
 may indicate that there might be some local structures or 
binding molecules that block the 3F4 epitope. We have noticed that the affinity of 3F4 for rPrP
Sc
 from 
VPSPr was increased in the preparations after purification steps compared to unpurified total brain 
homogenates (Zou et al., unpublished data). Thus, purification procedures may somehow remove the 
binding molecules or alter the local structures, which might make the 3F4 epitope exposed. On the 
other hand, all these findings may also suggest that PrP
Sc
 from VPSPr and fCJD
V180I
 have an origin 
different from PrP
Sc
 detected in other human prion diseases. Using the same 1E4 antibody, we 
previously identified a PK-resistant PrP species termed insoluble PrP
C
 (iPrP
C
) in uninfected human 
brains and cultured cells [6,9,40,41,42]. The small amount of PK-resistant PrP in uninfected brains and 
cells exhibited the same peculiar immunoreactivity behavior: higher affinity for 1E4 but lower affinity 
for 3F4. Remarkably, the resemblances of three PK-resistant PrP core fragments migrating at ~20 kDa, 
17 kDa and 7 kDa observed in VPSPr were detected with 1E4 in uninfected human brains [43]. The 
same immunoreactivity behavior of iPrP
C
 in uninfected brains and rPrP
Sc
 in VPSPr and fCJD
V180I
 
suggests that they may share a common molecular metabolic pathway or distribution and that VPSPr 
and fCJD
V180I
 may result from an increase in the amount of iPrP
C
 [43]. 
9. Association between VPSPr and Other Prion Diseases  
In addition to V180I and T183A mutations, three other naturally occurring PrP mutations including 
D178N, F198S, and E200K linked to familial prion disease have reportedly been associated with 
altered ratios of the three PrP glycoforms. But all the three familial prion diseases do not have rPrP
Sc
 
that lacks diglycosylated form [39]. Moreover, the 1E4-preferentially detectable rPrP
Sc
 has not been 
identified yet. The deposition in the brain of multiple small PK-resistant PrP
Sc
, especially the 7-kDa 
fragment is the molecular hallmark of GSS [44]. Therefore, it is reasonable for us to anticipate some 
potential association between GSS and VPSPr. Indeed, because of the long disease duration, multiple 
PK-resistant PrP fragments, and variable PK-resistance of PrP
Sc
, VPSPr was once suspected to be the 
sporadic form of GSS associated with PrP
A117V
 mutation (GSS
A117
) [5]. However, we also observed 
different ratios and immunoreactivity of PrP
Sc
 between VPSPr and GSS
A117V
 in the same study. It is 
known that GSS is frequently associated with a predominantly cerebellar dysfunction and is mainly 
characterized by the deposition of multicentric plaques in the cerebellum [39]. In contrast, VPSPr lacks 
typical multicentric plaques while it exhibits dot-like staining or small plaque-like formations in the 
cerebellum [5]. Whether VPSPr is the sporadic form of fCJD
V180I 
or GSS
A117V
 needs to be further 
determined. It is conceivable that cells and animals expressing human PrP
V180I
 or PrP
A117V 
will provide 
valid models for addressing the outstanding questions. 
Pathogens 2013, 2 467 
 
The fact that a small PK-resistant rPrP
Sc
 migrating at ~6–7 kDa that has been believed to be a 
molecular hallmark of various GSS is also detectable in both VPSPr and Nor98 [2,5,7,34,35,44] may 
imply a possible association among these diseases. To gain insights into their apparent similarity and 
difference and to investigate possible relationships among them, we further compared the small 
fragment from VPSPr, Nor98, various GSS linked to P102L, A117V, or F198S PrP mutation [8,45]. It 
was demonstrated that VPSPr and Nor98 share both similar and distinctive features. For instance, 
interestingly, they all have a core rPrP
Sc
 fragment encompassing PrP97-142 while the fragment can 
have varied N- and C-terminal cleavage sites (Table 1) [45].  
Table 1. Antibody mapping of the 6–7 kDa small rPrPSc [45]. 
MAbs Epitopes 
Human Sheep 
VPSPr A117 F198S 102 sCJD Nor98 
SAF32 Octarepeat – – + + + – 
12B2 89–93 – + + + + + 
9A2 99–101 ± + + + + + 
6D11 93–109 + + + + + + 
8G8 95–110 + + + + + + 
F89 139–142 + + + + + + 
L42 145–150 + ± ± + + + 
12F10 143–152 + – – – + – 
Repeat region amino acids: 59–65; 67–73; 75–81; 83–89–: No signal; +: strong signal; and +/–: week signal.  
10. Conclusions 
Prions found in sporadic VPSPr are clearly different from those of all other classic sporadic human 
prion diseases. Both VPSPr and fCJD
V180I
 shares similar physicochemical properties of PrP
Sc
 and a 
glycoform-selective prion formation pathway. The finding of the effect of polymorphism at residue 
129 on the levels of rPrP
Sc
 and sPrP
Sc
 further emphasizes the role of the polymorphism in the 
pathogenesis of human prion diseases. The two diseases specifically alter glycosylation at the first 
glycosylation site at residue 181 of PrP, which may involve a non-PrP protein that participates in 
regulating PrP glycosylation. Because of similar immunoreactivity and enzymatic fragmentation, PrP
Sc
 
in VPSPr and fCJD
V180I
 may have an origin similar to iPrP
C
. The possible correlation between human 
VPSPr and sheep Nor98 is interesting but remains to be further investigated. The low transmissibility 
of VPSPr and fCJD
V180I
 may result from altered posttranslational modifications including not only 
glycosylation but also the glycophosphatidylinositol (GPI) anchor. Whether there are any changes in 
GPI anchor remains unknown. Our current protein sequencing study and glycan analysis of purified 
rPrP
Sc
 will provide insights into these issues. Future studies with the two diseases and with cell and 
animal models expressing PrP
V180I
 mutation will help us understand the possible co-factors and molecular 
mechanisms underlying the formation of the unique prions identified in VPSPr and fCJD
V180I
.  
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